Stanford Gives Up Cancer Treatment Patent In Europe
Stanford University has relinquished its European patent for a type of cancer treatment following a challenge from Pfizer and Danish biotech company Genmab, an appeals panel found in a ruling released...To view the full article, register now.
Already a subscriber? Click here to view full article